Intellicell Biosciences, Inc. (OTC: SVFC) Penny Stock to Watch!
SVFC has made an explosive move up off its $0.15 base!
Intellicell Biosciences, Inc. (OTC: SVFC) was base lined for months in the $0.15 range before trying to make an explosive move up in December of last year. Since then the stock has continued to drift downwards but still manages to hold the $0.15 base.
SVFC is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using adult autologous vascular cells (SVC's) derived from the blood vessels in the adult adipose tissue. The Company has developed its own patent pending protocol to separate adult autologous vascular cells from adipose tissue without the use of enzymes. IntelliCell will also be seeking to develop technology-licensing agreements with technology developers, universities, and international business entities.
According to SVFC there is a massive demand for this Stem Cell technology and the major Orthopedic Sports Doctors have long known that the stem cells from fat, which is really soup cells from the blood vessels of the fat, would become the greatest sports medicine in the world. Up until recently sports players went oversees and to the Caribbean and Latin America to be treated because of the success of the use of these multi potent cells including Bartolo Colon and several others. Because of IntelliCell's invention, people can now receive this medicine in the United States.
SVFC has about $330,000 in the treasury and total assets of just over $4 million. The Company has a significant debt load of $6 million + including a $1.3 million convertible debenture. To date SVFC has had minimal revenues and continues to burn significant cash. Since inception the Company has cumulative losses of $19 million +.
Conclusion: SVFC has been base lined at the $0.15 range for months. Technically the stock is sound for gains from current levels as the Company continues to update shareholders regularly on significant progress. Penny Stocks involved in Stem Cell in the past have a history of highly explosive moves up and SCFC is definitely a stock to watch here.
To find out the inside scoop on SVFC subscribe to OTCMagic.com right now. Also everyone should know, we have something HUGE coming!
Intellicell Biosciences, Inc.
Robert J. Sexauer
SYMBOL: OTC: SVFC
Shares Outstanding 32,883,235
Market Cap: $9,207,306
Intellicell Biosciences, Inc. (OTC: SVFC) was formed under the name Regen Biosciences, Inc. on August 13, 2010 as a pioneering regenerative medicine company to develop and commercialize regenerative medical technologies in large markets with unmet clinical needs. On February 17, 2011, Regen Biosciences, Inc. changed its name to IntelliCell BioSciences Inc. To date, IntelliCell has developed proprietary technologies that allow for the efficient and reproducible separation of stromal vascular fraction containing adipose stem cells that can be performed in tissue processing centers and in doctors’ offices.
On November 15 SVFC announced that it has been notified according to the FDA validation registration number 3009842420, that its new facility located at 460 Park Avenue, New York, NY 10022 is now registered to recover, process, package, store, and label human cells and tissue products (HCT/P's) such as the IntelliCell autologous stromal vascular fraction cellular product. The registration is required under FDA's HCT/P regulations, found at 21 CFR 1271. The registration does not represent FDA approval of IntelliCell's processes.
IntelliCell's CEO, Dr. Steven Victor, said, "Our Company is very pleased to announce today that our new cellular processing facility has now been registered to process an individual's own tissue for the purpose of acquiring their stem and regenerative cells for use in regenerative medicine. The IntelliCell processing technology is designed to allow physicians to treat their patients during a same day and same procedure basis much the same way that bone marrow transplants and IVF treatments are performed today. This is a significant step for the Company as it continues its mission to be a leading regenerative medicine company. We look forward to continuing to work with FDA as we prepare a number of clinical studies for disease states with high unmet clinical needs."
Formerly=Media Exchange Group, Inc. until 7-2011
Formerly=China Wireless Communications, Inc. until 5-2011
Formerly=i-Track, Inc. until 3-03
Capital Change=shs decreased by 1 for 20 split Pay date=12/02/2002.
Capital Change=shs decreased by 1 for 500 split. Pay date=05/06/2011.